Barclays analyst Gena Wang raised the firm’s price target on Legend Biotech to $65 from $53 and keeps an Overweight rating on the shares after the company reported Q4 Carvykti sales of $55M. The analyst raised the price target to reflect improved confidence in the drug’s earlier line opportunity.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on LEGN: